Skip to main content
SpringerLink
Log in

Brandname AIs linked to discontinuation, poor adherence

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Hershman DL, et al. The Change From Brand-Name to Generic Aromatase Inhibitors and Hormone Therapy Adherence for Early-Stage Breast Cancer. Journal of the National Cancer Institute 106: No. 11, Nov 2014. Available from: URL: http://dx.doi.org/10.1093/jnci/dju319

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brandname AIs linked to discontinuation, poor adherence. PharmacoEcon Outcomes News 715, 11 (2014). https://doi.org/10.1007/s40274-014-1669-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1669-2

Search

Navigation